I lend to life sciences companies after a decade in investment banking.
I underwrite the drug itself: will people use it, and would a pharma buyer want it in a downside case?
On Evercore's biopharma M&A team I also worked on Novo Nordisk's $1.8bn Emisphere deal.
After my UCL law degree, the law firms all rejected me, so I pivoted and started in sell-side M&A.
My high school accounting training turned out pretty helpful when I pivoted from law into banking.
I lend to life sciences companies after a decade in investment banking.
I underwrite the drug itself: will people use it, and would a pharma buyer want it in a downside case?
On Evercore's biopharma M&A team I also worked on Novo Nordisk's $1.8bn Emisphere deal.
After my UCL law degree, the law firms all rejected me, so I pivoted and started in sell-side M&A.
My high school accounting training turned out pretty helpful when I pivoted from law into banking.
By using this service, you agree to the Terms of Service and Privacy Policy.